TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07869264: An Observational Registry Study to Evaluate the Use and Safety of LEQEMBI in Routine Clinical Practice in Taiwan

Sponsor: Eisai Taiwan Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$426,800

Rescue Site Savings

+$271,600

Unlock Full NCT07869264 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07869264 Rescue Dossier →